<DOC>
	<DOCNO>NCT00706095</DOCNO>
	<brief_summary>This open-label , three-parallel group pharmacokinetic study . Patients advance solid tumor assign one three group receive I.V . dos eribulin ( E7389 ) . The three group : normal hepatic function , mild hepatic impairment ( Child-Pugh A ) moderate hepatic impairment ( Child-Pugh B ) accord Child-Pugh System classify hepatic impairment .</brief_summary>
	<brief_title>Study Of Eribulin ( E7389 ) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System</brief_title>
	<detailed_description />
	<criteria>1 . Patients must histologically cytologically confirm advanced solid tumor progress follow standard therapy standard therapy exists ( include surgery radiation therapy ) 2 . Age ≥ 18 year 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . 4 . Life expectancy ≥ 3 month 5 . Adequate renal function evidence serum creatinine ≤ 2.0 mg/dL calculate creatinine clearance ≥ 40 mL/minute ( min ) per Cockcroft Gault formula . 6 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , hemoglobin ≥ 10.0 g/dL ( hemoglobin &lt; 10.0 g/dL acceptable correct growth factor transfusion ) , platelet count ≥ 100 x 10^9/L 7 . Patients willing able comply study protocol duration study 8 . Written inform consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . Additional Inclusion Criteria Group Patients No Hepatic Impairment : All general inclusion criterion list plus : Normal hepatic function evidence bilirubin ≤ 34 μmol/l ( ≤2.0 mg/dL ) alkaline phosphatase , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) ≤3 time upper limit normal ( ULN ) ( case liver metastasis ≤5 x ULN ) , case bone metastasis , liver specific alkaline phosphatase ≤3 time upper limit normal ( ULN ) , case concomitant liver metastasis , ≤5 x ULN . Additional Inclusion Criteria Group Patients Hepatic Impairment : All general inclusion criterion list plus : Mild ( ChildPugh A ) moderate ( ChildPugh B ) hepatic dysfunction accord ChildPugh scoring system criterion , patient laboratory value within normal range include ChildPugh A category Or , Moderate hepatic dysfunction ( ChildPugh B ) accord ChildPugh scoring system criteria 1 . Patients receive follow treatment within specified period E7389 treatment start : 1 . Chemotherapy , radiation , biological therapy within 3 week . 2 . Hormonal therapy within 1 week . 3 . Any investigational drug within 4 week . 2 . Patients clinically significant laboratory abnormality except parameter influence hepatic impairment . 3 . Patients severe ( ChildPugh C ) hepatic dysfunction accord ChildPugh scoring system . 4 . Patients encephalopathy ≥ Grade 1 . 5 . Patients receive drug know induce inhibit CYP3A4 activity . Clinically significant drug list comprehensive list find http : //medicine/iupui.edu/flockhart/table.htm . 6 . Patients , require therapeutic anticoagulant therapy line patency warfarin related compound change heparinbased therapy , eligible . 7 . Women pregnant breastfeeding ; woman childbearing potential either positive pregnancy test screening pregnancy test ; woman childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 8 . Fertile men willing use contraception fertile men female partner willing use contraception 9 . Severe/uncontrolled intercurrent illness/infection . 10 . Significant cardiovascular impairment ( history congestive heart failure &gt; New York Heart Association [ NYHA ] Grade II , unstable angina myocardial infarction within past six month , serious cardiac arrhythmia ) . 11 . Patients organ allograft require immunosuppression ( include blood blood component transfusion ) . 12 . Patients know positive HIV status . 13 . Patients brain subdural metastasis eligible , unless stable complete local therapy discontinue use corticosteroid indication least four week start treatment E7389 . 14 . Patients meningeal carcinomatosis . 15 . Patients hypersensitivity halichondrin B and/or halichondrin Blike compound . 16 . Patients participate prior E7389 clinical trial . 17 . Patients preexist neuropathy &gt; Grade 2 . 18 . Patients significant disease disorder , Investigator 's opinion , would exclude patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>